Treatment Information

Back

Bladder Cancer treatment details. Chemotherapy.

Georges Pompidou Hospital, University Paris Descartes, Paris, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Paris
Treatments:ChemotherapyHospital:Georges Pompidou Hospital, University Paris Descartes
Drugs:Journal:Link
Date:Nov 2014

Description:

Patients:
This phase 2 study involved patients with advanced or metastatic, HER2-overexpressing urothelial carcinoma who were separated into two treatment groups. Group A consisted of 29 patients with a median age of 66 years and 93% were male. Group B had 32 patients with a median age of 64 years and 84% were male.

Treatment:
Patients in group A received chemotherapy with gemcitabine and either cisplatin or carboplatin.
Patients in group B received biologic therapy with trastuzumab in addition to chemotherapy with gemcitabine and either cisplatin or carboplatin

Toxicities:
The most severe toxicities in group A were of grade 4 and included grade 3-4 neutropenia, anemia, and diarrhea. Grade 1-2 nausea and constipation were also reported.

There was one treatment-related death due to febrile neutropenia in group B. Grade 3-4 anemia, nausea/vomiting, and diarrhea were also reported.

Results:
The median overall survival rates for groups A and B were 15.7 and 14.1 months, respectively.

Support:
This study was supported by Roche SAS.

Correspondence: Dr. Stephane Oudard; email: [email protected]



Back